PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial in infants and toddlers.
Sanofi, SK Bioscience Launch Phase III Trial Program to Develop PCV21 for Pneumococcal Conjugate Vaccines